About this iReport
  • Not verified by CNN

  • Click to view localinsight's profile
    Posted February 20, 2015 by

    More from localinsight

    Danish Study Links Depakote to Autism


    A Danish research study discovered that moms who took the anti-seizure medication Depakote throughout pregnancy were five times more likely have a child diagnosed with autism as moms who did not take the drug.
    The research monitored over 665,000 Danish youngsters from 1996 to 2006, 5,500 of whom were detected with autism. Of these, 508 were born to moms who took a valproate drug like Depakote throughout pregnancy. Moms who took valproate drugs throughout pregnancy had a 4.42 % possibility of having a youngster with autism, while moms who did not take the drug had just a 1.02 % opportunity.
    In April 2013 the Journal of the American Medical Association (JAMA) released a short article labeled Prenatal Valporate [Depakote] Direct exposure and the Risk of Autism Spectrum Disorders and Childhood Autism. The short article specified that using Depakote throughout pregnancy "was related to a substantially enhanced danger of autism in the offspring, even after accounting for adult psychiatric illness and epilepsy."
    Scientists think the drug influences the development of the nerves, which it occurs extremely early in the pregnancy. This can result in issues for females who have unexpected pregnancies who might take the drug as recommended prior to becoming aware that they are pregnant. Neurologists now suggest that females of child-bearing age use alternative medications to treat their signs and symptoms, or continue only at an extremely low dosage.
    Depakote is a psychiatric drug that works by enhancing the quantity of the natural chemical gamma amminobutyric acid (GABA) in the brain. Enhanced GABA levels diminishes brain signals that can cause seizures. Depakote is likewise utilized to deal with bipolar and manic episodes as well as migraine headache headaches.
    Additionally, Depakote use throughout pregnancy has also been connected to an enhanced threat of spina bifida and other neural tube flaws, additional fingers or toes (polydactyl), heart flaws (consisting of atrial septal problem), malformed limbs, skull or brain, cleft palate, and cognitive specials needs.
    The label also cautions for pancreatitis, liver failure, and abnormality. The FDA designates Depakote as a schedule D drug, meanings that it can hurt unborn children and ought to not be taken by pregnant women, or women who believe that they may become pregnant.
    Adverse effects consist of exhaustion, sluggish psychological procedures, queasiness, tremblings, hair loss and weight gain. Women who take Depakote are also most likely to establish polycystic ovarian syndrome, which can trigger ovarian cysts and influence a female's capability to conceive.
    Abbot Laboratories, the business that makes Depakote, was made to pay over $1.6 billion in fines for unlawful advertising. A class-action Depakote lawsuit was submitted versus the business in 2012 in Illinois by 27 victims asserting that Depakote had directly caused different abnormalities in their kids, inlcuding developmental delays, spina bifida, cleft palate and other physical malformations. The business included autism to the caution label for the drug in August 2014, more than a year after the release of the JAMA article.

    Add your Story Add your Story